Use of proton pump inhibitors and mortality after hip fracture in a nationwide study

[1]  R. Trickett,et al.  Prophylactic proton pump inhibitors in femoral neck fracture patients - A life - and cost-saving intervention. , 2016, Annals of the Royal College of Surgeons of England.

[2]  P. Nasiri,et al.  Correlation of Bone Mineral Density Scores and Proton Pump Inhibitors Use in the Elderly. , 2016, Current rheumatology reviews.

[3]  S. Corrao,et al.  Gender difference in drug use in hospitalized elderly patients. , 2015, European journal of internal medicine.

[4]  J. Zwerina,et al.  Mortality After Hip Fracture in Austria 2008–2011 , 2014, Calcified Tissue International.

[5]  J. Zwerina,et al.  Mortality After Hip Fracture in Austria 2008–2011 , 2014, Calcified Tissue International.

[6]  C. Cooper,et al.  The impact of common co-morbidities (as measured using the Charlson index) on hip fracture risk in elderly men: a population-based cohort study , 2014, Osteoporosis International.

[7]  E. Kuipers,et al.  A Benefit–Risk Assessment of the Use of Proton Pump Inhibitors in the Elderly , 2014, Drugs & Aging.

[8]  E. di Giulio,et al.  Proton pump inhibitor therapy and potential long-term harm , 2014, Current opinion in endocrinology, diabetes, and obesity.

[9]  Wei Zhao,et al.  Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. , 2013, JAMA.

[10]  S. Bandinelli,et al.  Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. , 2013, Bone.

[11]  C. Cooper,et al.  Osteoporosis in the European Union: medical management, epidemiology and economic burden , 2013, Archives of Osteoporosis.

[12]  B. Iglseder,et al.  Stress ulcer prophylaxis, thromboprophylaxis and coagulation management in patients with hip fractures , 2013, Wiener Medizinische Wochenschrift.

[13]  P. Emery,et al.  Nonsteroidal Anti-Inflammatory Drugs, Gastroprotection, and Benefit–Risk , 2013, Pain practice : the official journal of World Institute of Pain.

[14]  S. Wilhelm,et al.  Perils and pitfalls of long-term effects of proton pump inhibitors , 2013, Expert review of clinical pharmacology.

[15]  H. Song,et al.  A population-based case–control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate , 2013, Journal of Gastroenterology.

[16]  N. Vakil.  Prescribing Proton Pump Inhibitors , 2012, Drugs.

[17]  Alicia R. Desilets,et al.  Considerations for the use of proton-pump inhibitors in older adults. , 2012, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[18]  Xin-ji Zhang,et al.  Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis , 2011, European journal of gastroenterology & hepatology.

[19]  G. Leontiadis,et al.  Proton Pump Inhibitors and Risk of Fracture: A Systematic Review and Meta-Analysis of Observational Studies , 2011, The American Journal of Gastroenterology.

[20]  R. Eastell,et al.  Proton pump inhibitor use and the antifracture efficacy of alendronate. , 2011, Archives of internal medicine.

[21]  D. Bauer,et al.  Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. , 2011, The American journal of medicine.

[22]  D. Metz,et al.  Systematic Review of the Epidemiology of Complicated Peptic Ulcer Disease: Incidence, Recurrence, Risk Factors and Mortality , 2011, Digestion.

[23]  Y. Loke,et al.  Meta-analysis: risk of fractures with acid-suppressing medication. , 2011, Bone.

[24]  C. Meier,et al.  Proton Pump Inhibitors and Fracture Risk , 2010, Drug safety.

[25]  J. Inadomi,et al.  Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. , 2010, The American journal of managed care.

[26]  C. Cooper,et al.  Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study , 2010, Osteoporosis International.

[27]  M. Howell,et al.  Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. , 2010, Archives of internal medicine.

[28]  Cathleen S. Colón-Emeric,et al.  Meta-analysis: Excess Mortality After Hip Fracture Among Older Women and Men , 2010, Annals of Internal Medicine.

[29]  Eve Donnelly,et al.  The assessment of fracture risk. , 2010, The Journal of bone and joint surgery. American volume.

[30]  S. Boonen,et al.  Potential mediators of the mortality reduction with zoledronic acid after hip fracture , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  A. Pilotto,et al.  Acid-related disorders in the elderly. , 2009, Best practice & research. Clinical gastroenterology.

[32]  Michael D Howell,et al.  Acid-suppressive medication use and the risk for hospital-acquired pneumonia. , 2009, JAMA.

[33]  D. Bauer,et al.  Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older Adults , 2008, Calcified Tissue International.

[34]  K. Rothman,et al.  Using prescription claims data for drugs available over‐the‐counter (OTC) , 2007, Pharmacoepidemiology and drug safety.

[35]  Yu-Xiao Yang,et al.  Long-term proton pump inhibitor therapy and risk of hip fracture. , 2006, JAMA.

[36]  L. Fisher,et al.  Perioperative acute upper gastrointestinal haemorrhage in older patients with hip fracture: incidence, risk factors and prevention , 2006, Alimentary pharmacology & therapeutics.

[37]  A. Murray,et al.  Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. , 2005, The American journal of medicine.

[38]  E. Bini,et al.  Endoscopic treatment compared with medical therapy for the prevention of recurrent ulcer hemorrhage in patients with adherent clots. , 2003, Gastrointestinal endoscopy.

[39]  K. Abe,et al.  Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans , 1993, Calcified Tissue International.

[40]  E. Savarino,et al.  The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. , 2017, European journal of internal medicine.

[41]  J. Zwerina,et al.  Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study , 2015, Osteoporosis International.

[42]  Y. Huang,et al.  Proton-pump inhibitors and risk of fractures: an update meta-analysis , 2015, Osteoporosis International.

[43]  MS Sandeep Vijan MD,et al.  Defining Appropriate Use of Proton-Pump Inhibitors Among Medical Inpatients , 2015, Journal of General Internal Medicine.

[44]  P. Eiken,et al.  Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study , 2012, Osteoporosis International.

[45]  C. Cooper,et al.  Osteoporosis: trends in epidemiology, pathogenesis and treatment , 2006 .

[46]  F. Rengo,et al.  Drug use by the elderly in general practice: effects on upper gastrointestinal symptoms , 2005, European Journal of Clinical Pharmacology.

[47]  R. Poon,et al.  Risk factors for rebleeding and death from peptic ulcer in the very elderly , 1998, The British journal of surgery.